Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Lupus Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Lupus Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and quantity-limit coverage for Benlysta, Lupkynis, and Saphnelo products used for lupus-related indications in Boeing commercial plans.

    Policy Summary
    PayerPrime Therapeutics
    PolicyLupus Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for Benlysta, Lupkynis, and Saphnelo with the applicable clinical criteria and documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered specialty drug products
    12 monthsApproval length
    4 per 28 daysBenlysta and Saphnelo limit
    180 per 30 daysLupkynis limit
    90 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Continuation lookback

    Coverage Criteria

    Initial Therapy Criteria

    Target agents will be approved when ALL of the following are met.

    Initial evaluation

    • Therapy pathway

      • Continuation eligibility at initial review: The requested agent is eligible for continuation of therapy; the prescriber states that the patient has been treated with the requested agent within the past 90 days, treatment did not consist only of samples, and the patient is at risk if therapy is changed.Within the past 90 days

        All target agents are eligible for continuation therapy.

      • New-start pathway

        • Indication

          • Active SLE without active lupus nephritis: The requested agent is FDA-labeled or compendia-supported for SLE; if the requested agent is Saphnelo, the patient has moderate to severe SLE; the patient has tried and had an inadequate response to hydroxychloroquine or has hydroxychloroquine intolerance, hypersensitivity, or an FDA-labeled contraindication; and the patient has tried and had an inadequate response to one corticosteroid or immunosuppressive agent, or has the corresponding intolerance, hypersensitivity, or FDA-labeled contraindication.
          • Another supported indication: The patient has another indication supported in compendia for the requested agent and route of administration.AHFS or DrugDex evidence level 1, 2a, or 2b
        • Background therapy: For active SLE without active lupus nephritis, the patient is currently treated with standard SLE therapy and will continue it in combination with the requested agent. For active lupus nephritis, the patient uses background immunosuppressive lupus-nephritis therapy in combination with the requested agent; examples include corticosteroids plus mycophenolate for Lupkynis, and corticosteroids plus mycophenolate, azathioprine, or cyclophosphamide for Benlysta.
        • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a rheumatologist or nephrologist, or has consulted with such a specialist.
        • Benlysta requirements when applicable: The patient does not have severe active central nervous system lupus. Benlysta is not used with Lupkynis unless the patient has active lupus nephritis, has tried and had an inadequate response to two standard therapy courses, and will use Benlysta with Lupkynis plus mycophenolate; medical records are required. Combination with another immunomodulatory agent requires compatible prescribing information and support from clinical trials, phase III studies, or guidelines.Two failed standard therapy courses for exceptional Benlysta/Lupkynis combination
        • Lupkynis requirements when applicable: The patient will not use Lupkynis with cyclophosphamide or Saphnelo. Lupkynis is not used with Benlysta unless the patient has active lupus nephritis, has tried and had an inadequate response to two standard therapy courses, and will use Lupkynis with Benlysta plus mycophenolate; medical records are required.Two failed standard therapy courses for exceptional Lupkynis/Benlysta combination
        • Saphnelo requirements when applicable: The patient does not have severe active lupus nephritis or severe active central nervous system lupus and will not use Saphnelo with Lupkynis. Combination with another immunomodulatory agent requires compatible prescribing information and support from clinical trials, phase III studies, or guidelines.
        • Contraindications: The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation or Renewal Therapy

    Target agents will be approved for renewal when ALL of the following are met.

    Renewal evaluation

    • Active SLE without active lupus nephritis: If applicable, the patient is currently treated with standard SLE therapy and will continue standard SLE therapy in combination with the requested agent. Standard therapy includes corticosteroids, hydroxychloroquine, azathioprine, methotrexate, mycophenolate, or cyclophosphamide.
    • Active lupus nephritis: If applicable, the patient is currently treated with and will continue background immunosuppressive lupus-nephritis therapy in combination with the requested agent. Examples include corticosteroids plus mycophenolate for Lupkynis, and corticosteroids plus mycophenolate, azathioprine, or cyclophosphamide for Benlysta.
    • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a rheumatologist or nephrologist, or has consulted with such a specialist.

    Quantity-Limit Approval

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met.

    Quantity-limit approval

    • Standard approval: The requested quantity or dose does not exceed the program quantity limit.
    • Higher-dose exception without FDA maximum: The requested quantity or dose exceeds the program quantity limit; the requested agent does not have a maximum FDA-labeled dose for the requested indication; and there is support for therapy with a higher dose for the requested indication.
    • Higher-strength substitution exception: The requested quantity or dose exceeds the program quantity limit; the requested quantity or dose does not exceed the maximum FDA-labeled dose for the requested indication; and there is support for why the requested quantity or dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.

    Product-specific restrictions apply to requested therapy. Benlysta is not covered for patients with severe active central nervous system lupus and generally may not be used with Lupkynis. The Benlysta–Lupkynis combination is considered only for active lupus nephritis after inadequate response to two standard therapy courses, with the combination used with mycophenolate and medical records submitted. Lupkynis must not be used with cyclophosphamide or Saphnelo, and Saphnelo must not be used with Lupkynis or in patients with severe active lupus nephritis or severe active central nervous system lupus.

    For combinations with another immunomodulatory agent, the requested product's prescribing information must not limit concomitant use, and supporting evidence such as clinical trials, phase III studies, or guidelines must be submitted.

    The requested therapy must not be used concomitantly with any agent identified in the policy's Agents NOT to be used Concomitantly list. The list includes numerous biologic, targeted, immunomodulatory, and immunosuppressive products, including Abrilada, Actemra, Adalimumab, Benlysta, Dupixent, Humira, Orencia, Rinvoq, Rituxan, Saphnelo, Stelara, Taltz, Xeljanz, Xolair, and other listed agents.

    Concomitant use with a listed agent may result in denial or nonapproval. Review the complete policy list before submitting a request involving combination therapy.

    Initial Therapy Criteria

    Initial Quantity-Limit Authorization

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met.

    Quantity-limit authorization

    • Standard quantity pathway: The requested quantity or dose does not exceed the program quantity limit.
    • Higher-dose exception without FDA maximum: The requested quantity or dose exceeds the program quantity limit; the requested agent does not have a maximum FDA-labeled dose for the requested indication; and there is support for therapy with a higher dose for the requested indication.
    • Higher-strength substitution exception: The requested quantity or dose exceeds the program quantity limit; the requested quantity or dose does not exceed the maximum FDA-labeled dose for the requested indication; and there is support for why the requested quantity or dose cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.

    Continuation and Renewal Criteria

    Continuation Therapy

    Renewal approval requires ALL of the following.

    Continuation therapy

    • Standard SLE therapy when applicable: For active SLE without active lupus nephritis, the patient is currently treated with and will continue standard SLE therapy in combination with the requested agent. Standard therapy includes corticosteroids, hydroxychloroquine, azathioprine, methotrexate, mycophenolate, or cyclophosphamide.
    • Lupus-nephritis background therapy when applicable: For active lupus nephritis, the patient is currently treated with and will continue background immunosuppressive lupus-nephritis therapy in combination with the requested agent. Examples include corticosteroids plus mycophenolate for Lupkynis, and corticosteroids plus mycophenolate, azathioprine, or cyclophosphamide for Benlysta.
    • Specialist involvement: The prescriber is a specialist in the area of the patient's diagnosis, such as a rheumatologist or nephrologist, or has consulted with such a specialist.

    Required Prior Therapy

    StepApplicable conditionRequired prior therapy
    1Active systemic lupus erythematosus (SLE) without active lupus nephritis (LN)The patient must have tried hydroxychloroquine with an inadequate response, or have intolerance, hypersensitivity, or an FDA-labeled contraindication to hydroxychloroquine; and must have tried one corticosteroid or immunosuppressive agent with an inadequate response, or have the corresponding intolerance, hypersensitivity, or FDA-labeled contraindication.
    StepApplicable conditionRequired prior therapy
    2Exceptional Benlysta-plus-Lupkynis or Lupkynis-plus-Benlysta combination therapy in active lupus nephritisThe patient must have tried and had an inadequate response to two standard therapy courses and must use the requested combination with mycophenolate. Medical records are required.

    Product Quantity Limits

    Quantity Limit
    ProductBenlysta (belimumab) subcutaneous solution auto-injector, 200 MG/ML
    Quantity limit4 pens
    Day supply28 days
    Quantity Limit
    ProductBenlysta (belimumab) subcutaneous solution prefilled syringe, 200 MG/ML
    Quantity limit4 syringes
    Day supply28 days

    Provider Requirements and Review Outcomes

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for covered Benlysta (belimumab), Lupkynis (voclosporin), and Saphnelo (anifrolumab-fnia) products before approval under this program.

    • Benlysta: belimumab 200 mg/mL pens or prefilled syringes.
    • Lupkynis: voclosporin 7.9 mg capsules.
    • Saphnelo: anifrolumab-fnia 120 mg/0.8 mL prefilled syringes or pens.
    Prior Authorization

    12-Month Approval Period

    Initial and renewal authorizations are generally approved for 12 months when all applicable clinical criteria are met. Patients not previously approved through the plan’s prior authorization process require initial evaluation.

    • Initial approval period: 12 months.
    • Renewal approval period: 12 months.
    • Renewals require prior plan approval and documented clinical benefit.

    Policy Background

    This policy addresses specialty medicines for systemic lupus erythematosus (SLE), including active SLE without active lupus nephritis and active lupus nephritis. Coverage is tied to the patient's indication, required background therapy, specialist involvement, and product-specific restrictions.

    For active SLE without lupus nephritis, the patient must be receiving and continue standard SLE therapy in combination with the requested agent. For active lupus nephritis, the requested agent must be used with appropriate background immunosuppressive therapy, such as corticosteroids plus mycophenolate for Lupkynis or corticosteroids plus mycophenolate, azathioprine, or cyclophosphamide for Benlysta.

    Definitions and Supporting Standards

    Compendia Allowed
    Accepted compendiumAHFS
    Accepted compendiumDrugDex
    Evidence levels1, 2a, or 2b
    Eligible for Continuation of Therapy
    Eligible agentsAll target agents are eligible for continuation-of-therapy review
    Initial-review treatment historyThe patient must have been treated with the requested agent within the past 90 days
    Change in therapyThe prescriber must state that the patient is at risk if therapy is changed
    Policy Summary
    PayerPrime Therapeutics
    PolicyLupus Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests for Benlysta, Lupkynis, and Saphnelo with the applicable clinical criteria and documentation.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Renewal CriteriaRequired Prior TherapyProduct Quantity LimitsProvider Requirements and Review OutcomesPolicy BackgroundDefinitions and Supporting Standards
    Benlysta renewal requirements: The patient does not have severe active central nervous system lupus. Benlysta is not used with Lupkynis unless the patient has active lupus nephritis, has tried and had an inadequate response to two standard therapy courses, and will use Benlysta with Lupkynis plus mycophenolate; medical records are required. Combination with another immunomodulatory agent requires compatible prescribing information and support from clinical trials, phase III studies, or guidelines.Two failed standard therapy courses for exceptional Benlysta/Lupkynis combination
  1. Lupkynis renewal requirements: The patient will not use Lupkynis with cyclophosphamide or Saphnelo. Lupkynis is not used with Benlysta unless the patient has active lupus nephritis, has tried and had an inadequate response to two standard therapy courses, and will use Lupkynis with Benlysta plus mycophenolate; medical records are required.Two failed standard therapy courses for exceptional Lupkynis/Benlysta combination
  2. Saphnelo renewal requirements: The patient does not have severe active lupus nephritis or severe active central nervous system lupus and will not use Saphnelo with Lupkynis. Combination with another immunomodulatory agent requires compatible prescribing information and support from clinical trials, phase III studies, or guidelines.
  3. Contraindications: The patient does not have any FDA-labeled contraindications to the requested agent.
  4. Product-specific restrictions: The patient meets the applicable Benlysta, Lupkynis, and Saphnelo restrictions, including prohibited concomitant-use restrictions and requirements for exceptional Benlysta-plus-Lupkynis or Lupkynis-plus-Benlysta therapy. Combination with another immunomodulatory agent requires compatible prescribing information and supporting clinical evidence.
  5. Contraindications: The patient does not have any FDA-labeled contraindications to the requested agent.
  6. Quantity Limit
    ProductLupkynis (voclosporin) capsule, 7.9 MG
    Quantity limit180 capsules
    Day supply30 days
    Quantity Limit
    ProductSaphnelo (anifrolumab-fnia) solution prefilled syringe, 120 MG/0.8
    Quantity limit4 syringes
    Day supply28 days
    Quantity Limit
    ProductSaphnelo pen (anifrolumab-fnia) solution auto-injector, 120 MG/0.8
    Quantity limit4 pens
    Day supply28 days
    Billing Rule

    Quantity-Limit Approval Criteria

    Quantity-limit approval requires that the requested dose not exceed the applicable program limit, or that the request satisfy an exception pathway for a higher quantity.

    • Benlysta 200 mg/mL pens: 4 per 28 days.
    • Benlysta 200 mg/mL prefilled syringes: 4 per 28 days.
    • Lupkynis 7.9 mg capsules: 180 per 30 days.
    • Saphnelo 120 mg/0.8 mL syringes or pens: 4 per 28 days.
    Prior Authorization

    Approval Duration and Benlysta Loading Dose

    Quantity-limit approvals are generally effective for 12 months. If an initial Benlysta loading dose is approved, authorize the FDA-labeled loading dose for 1 month, followed by maintenance dosing for the remainder of the authorization.

    • Standard approval duration: 12 months.
    • Benlysta initial loading dose: 1 month per FDA labeling.
    • Maintenance dosing follows the loading-dose period.
    Step Therapy

    Hydroxychloroquine and Second-Agent History

    For active SLE without active lupus nephritis, document that the patient tried hydroxychloroquine with inadequate response, or has intolerance, hypersensitivity, or an FDA-labeled contraindication. Also document inadequate response, intolerance, hypersensitivity, or contraindication to one corticosteroid or immunosuppressive agent such as azathioprine, methotrexate, mycophenolate, or cyclophosphamide.

    • Hydroxychloroquine history is required unless intolerance, hypersensitivity, or an FDA-labeled contraindication is documented.
    • A second-agent history is required for one corticosteroid or immunosuppressive agent.
    • The requested agent must be FDA labeled or compendia supported for SLE; Saphnelo requires moderate-to-severe SLE.
    Step Therapy

    Two Failed Standard Therapy Courses for Dual Therapy

    For exceptional Benlysta-plus-Lupkynis or Lupkynis-plus-Benlysta therapy in active lupus nephritis, document inadequate response to two standard therapy courses. The requested combination must include the applicable background therapy, and medical records are required.

    • Examples include corticosteroids plus Benlysta with mycophenolate, azathioprine, or cyclophosphamide.
    • Another example is corticosteroids plus Lupkynis with mycophenolate.
    • Benlysta-plus-Lupkynis requests require mycophenolate; Lupkynis-plus-Benlysta requests require mycophenolate.
    Documentation Required

    Recent Requested-Agent Treatment

    Continuation eligibility requires the prescriber to state that the patient has received the requested agent within the past 90 days and is at risk if therapy is changed. Treatment initiated only with samples is not approvable for this purpose.

    • Lookback period: within the past 90 days.
    • Document ongoing treatment with the requested agent.
    • Document risk associated with changing therapy.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Documentation Required

    Clinical and Prescriber Documentation

    Submit current and planned treatment details, including standard SLE or lupus nephritis background therapy, and identify the treating specialist or specialist consultation supporting the request.

    • For SLE without active LN, document current and continued standard therapy such as corticosteroids, hydroxychloroquine, azathioprine, methotrexate, mycophenolate, or cyclophosphamide.
    • For active LN, document background immunosuppressive therapy; examples include corticosteroids plus mycophenolate for Lupkynis and corticosteroids plus mycophenolate, azathioprine, or cyclophosphamide for Benlysta.
    • Prescriber must be a rheumatologist, nephrologist, or other specialist in the diagnosis area, or document specialist consultation.
    Documentation Required

    Quantity-Limit Exception Documentation

    Requests exceeding the program quantity limit require documentation supporting a permitted higher-dose exception.

    • If no maximum FDA-labeled dose exists for the indication, submit support for therapy at the higher dose.
    • If a maximum FDA-labeled dose exists, the requested quantity must not exceed it and documentation must explain why a lower quantity of a higher strength cannot be used within the program limit.
    Denial Risk

    Failure to Meet Clinical Approval Criteria

    Approval may be denied when the requested agent is not supported for the indication, required prerequisite therapy or treatment history is absent, or the submitted documentation does not establish the applicable criteria.

    • The diagnosis and requested route must be FDA labeled or supported by AHFS or DrugDex level 1, 2a, or 2b evidence when applicable.
    • Required hydroxychloroquine and second-agent history must be documented for applicable SLE requests.
    • Required background therapy, specialist involvement, clinical benefit, or medical records must be documented.
    • FDA-labeled contraindications to the requested agent preclude approval.
    Denial Risk

    Prohibited or Unsupported Combination Therapy

    Unsupported concomitant therapy can result in denial. The requested agent generally must not be combined with another immunomodulatory agent unless the prescribing information permits the combination and clinical evidence supports it.

    • Benlysta and Saphnelo require review of combinations with immunomodulatory agents such as TNF inhibitors, JAK inhibitors, and IL-4 inhibitors.
    • Lupkynis must not be used with cyclophosphamide or Saphnelo.
    • Benlysta and Lupkynis may be combined only for active LN after two failed standard therapy courses, with the required mycophenolate-containing regimen and medical records.
    • Saphnelo must not be combined with Lupkynis.
    Denial Risk

    Product-Specific Clinical Exclusions

    Product-specific exclusions apply. Benlysta is not approved for severe active CNS lupus; Lupkynis and Saphnelo have additional lupus nephritis and concomitant-therapy restrictions.

    • Benlysta: patient must not have severe active CNS lupus.
    • Lupkynis: patient must not use it with cyclophosphamide or Saphnelo; Benlysta combination is limited to the specified active-LN exception.
    • Saphnelo: patient must not have severe active lupus nephritis or severe active CNS lupus and must not use it with Lupkynis.
    Billing Rule

    Quantity-Limit Exceedance

    Claims exceeding the applicable product quantity limit require quantity-limit review and may not process under the standard limit.

    • Benlysta pens or syringes: more than 4 per 28 days requires review.
    • Lupkynis capsules: more than 180 per 30 days requires review.
    • Saphnelo syringes or pens: more than 4 per 28 days requires review.
    Denial Risk

    Quantity-Limit Exception Not Supported

    A quantity-limit exception may be denied when the request lacks adequate support for a higher dose or fails the FDA-labeled-dose and lower-quantity/higher-strength requirements.

    • Submit clinical support for a higher dose when no maximum FDA-labeled dose exists for the indication.
    • When a maximum FDA-labeled dose exists, the requested quantity must remain within that maximum.
    • Explain why a lower quantity of a higher strength cannot meet the treatment need within the program limit.
    Denial Risk

    Contraindicated Concomitant Therapy

    The requested agent must not be used concomitantly with agents listed as contraindicated concomitant therapy unless the policy criteria expressly provide an exception. Review the complete concomitant-agent list before submitting or approving therapy.

    • Listed agents include Abrilada, Actemra, Adalimumab, Adbry, Amjevita, Anzupgo, Arcalyst, Avsola, Avtozma, Benlysta, Bimzelx, Cibinqo, Cimzia, Cinqair, Cosentyx, Cyltezo, Dupixent, Ebglyss, Enbrel, Entyvio, Exdensur, Fasenra, Hadlima, Hulio, Humira, Hyrimoz, Icotyde, Idacio, Ilaris, Ilumya, Imuldosa, Inflectra, Infliximab, Kevzara, Kineret, Leqselvi, Litfulo, Nemluvio, Nucala, Olumiant, Omlyclo, Omvoh, Opzelura, Orencia, Otezla, Otezla XR, Otulfi, Pyzchiva, Remicade, Renflexis, Rhapsido, Riabni, Rinvoq, Rituxan, Rituxan Hycela, Ruxience, Saphnelo, Selarsdi, Siliq, Simlandi, Simponi, Simponi ARIA, Skyrizi, Sotyktu, Spevigo, Starjemza, Stelara, Steqeyma, Taltz, Tezspire, Tofacitinib, Tofidence, Tremfya, Truxima, Tyenne, Tyruko, Tysabri, Ustekinumab, Velsipity, Wezlana, Xeljanz, Xeljanz XR, Xolair, Yesintek, Yuflyma, Yusimry, Zeposia, and Zymfentra.
    SamplesTreatment started only with samples is not approvable